How does the scope of commercial success evidence relate to patent claims?

The scope of commercial success evidence must align with the scope of the patent claims. This means that the commercial success should be attributable to the specific features claimed in the patent application, not to unclaimed features or broader aspects of the product or process. The MPEP 716.03(a) provides an example: “Evidence showing commercial success…

Read More

What is the role of ‘comparative data’ in demonstrating unexpected results for patent applications?

What is the role of ‘comparative data’ in demonstrating unexpected results for patent applications? Comparative data plays a crucial role in demonstrating unexpected results for patent applications. The MPEP 716.02(b) states: “Evidence of unexpected results must be weighed against evidence supporting prima facie obviousness in making a final determination of the obviousness of the claimed…

Read More

What are the conditions for restarting prioritized examination after a request for continued examination (RCE)?

What are the conditions for restarting prioritized examination after a request for continued examination (RCE)? Prioritized examination can be restarted after an RCE under specific conditions. According to MPEP 708.02(b): “If an applicant files a request for continued examination (RCE) under 37 CFR 1.114 with a request for prioritized examination under 37 CFR 1.102(e) and…

Read More

How should an applicant respond to formal requirements in a patent application?

When responding to formal requirements in a patent application, an applicant should either: Comply with the formal requirements, or Specifically traverse each requirement not complied with The MPEP states: In all cases where reply to a requirement is indicated as necessary for further consideration of the claims, or where allowable subject matter has been indicated…

Read More

What are the requirements for invoking the joint research agreement provisions of 35 U.S.C. 102(b)(2)(C)?

To invoke the joint research agreement provisions of 35 U.S.C. 102(b)(2)(C), an applicant must: Amend the specification to disclose the names of the parties to the joint research agreement, if not already disclosed, in accordance with 37 CFR 1.71(g). Submit the required statement to invoke the prior art exception. According to the MPEP, this statement…

Read More